Researchers study peripheral blood Tregs as disease marker of gastric cancer

T-regulatory lymphocytes (Tregs) are a subset of T lymphocytes that are involved in the mechanism of immunotolerance to self- and allo-antigens. Activity of these cells is one of the mechanisms of immune evasion of tumors, which inhibits the antitumor activity of effector cells. Tregs are among the tumor-infiltrating lymphocytes and circulate in the peripheral blood. In various cancer types, increased prevalence of Tregs has been observed, and in some studies, this has been reported as a prognostic factor.

A research article published on January 21, 2011 in the World Journal of Gastroenterology addresses this question. The authors studied the peripheral blood Tregs as a potential disease marker, which was relatively easy to measure during pretreatment and follow-up periods.

The results indicated that the absolute number of Tregs in peripheral blood of gastric cancer but not colorectal cancer patients was significantly decreased in comparison with that in healthy controls. The findings suggest that the population of Tregs in peripheral blood does not simply mimic stromal Tregs. Further studies on larger groups of patients are necessary to evaluate the Treg population in cancer patients.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionary strategy offers hope for type 1 diabetes treatment